CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Barclays 26th Annual Global Healthcare Conference
Fireside Chat: Tuesday, March 12, 2024 at 4:35 pm ET
Location: Miami, FL
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Fireside Chat: Tuesday, March 26, 2024 at 2:30 pm ET
Location: Virtual
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.23 |
| Daily Change: | 0.02 0.68 |
| Daily Volume: | 1,859,520 |
| Market Cap: | US$278.040M |
July 21, 2025 June 25, 2025 June 25, 2025 March 20, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
